Globeflex Capital L P Acquires New Holdings in Collegium Pharmaceutical, Inc. $COLL

Key Points

• Globeflex Capital initiated a position in Collegium Pharmaceutical, purchasing 52,911 shares worth approximately $1.9 million, or about 0.16% of the company.
• Several institutional investors increased their holdings, including Millennium Management, which boosted its position by 248.5%, and Jane Street Group, which raised its stake by 218.7%.
• Collegium reported quarterly EPS of $1.92, exceeding the $1.72 consensus estimate, while revenue rose 6.3% year over year to $199.88 million. Analysts maintain a “Moderate Buy” consensus with an average price target of $51.

Globeflex Capital L P bought a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 52,911 shares of the specialty pharmaceutical company's stock, valued at approximately $1,915,000. Globeflex Capital L P owned about 0.16% of Collegium Pharmaceutical as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Collegium Pharmaceutical by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company's stock valued at $569,000 after purchasing an additional 825 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company's stock worth $19,338,000 after purchasing an additional 461,914 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Collegium Pharmaceutical by 7.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company's stock valued at $2,120,000 after buying an additional 4,625 shares during the period. Jane Street Group LLC raised its holdings in Collegium Pharmaceutical by 218.7% in the 1st quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company's stock valued at $3,926,000 after buying an additional 90,255 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Collegium Pharmaceutical by 3.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company's stock valued at $2,131,000 after buying an additional 2,592 shares during the last quarter.

Collegium Pharmaceutical Stock Up 0.9%

Shares of NASDAQ:COLL opened at $27.35 on Tuesday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03. Collegium Pharmaceutical, Inc. has a 52-week low of $25.47 and a 52-week high of $50.79. The business's 50 day simple moving average is $33.53 and its two-hundred day simple moving average is $35.56. The firm has a market cap of $890.52 million, a P/E ratio of 22.06 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The firm had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. During the same quarter in the previous year, the company posted $1.68 earnings per share. The company's quarterly revenue was up 6.3% on a year-over-year basis. As a group, research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

COLL has been the topic of a number of research reports. Weiss Ratings lowered shares of Collegium Pharmaceutical from a "hold (c)" rating to a "hold (c-)" rating in a report on Tuesday, August 11th. Zacks Research downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 28th. Piper Sandler reaffirmed a "neutral" rating and set a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. Wall Street Zen lowered Collegium Pharmaceutical from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Finally, Truist Financial upgraded Collegium Pharmaceutical to a "strong-buy" rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Collegium Pharmaceutical currently has an average rating of "Moderate Buy" and an average target price of $51.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source